|
Sign In to gain access to subscriptions and/or personal tools.
|
Tenofovir-Emtricitabine-Efavirenz in HIV-1-Infected Adults in Senegal: A 96-Week Pilot Trial in Treatment-Naive Patients
Roland Landman, MD*,
Marie Poupard,
M Diallo,
N F Ngom Gueye,
N Diakhate,
B Ndiaye,
C Toure Kane,
Aldo Trylesinski,
H Diop,
S Mboup,
M B Koita Fall,
Eric Deleporte,
A?da Benalycherif,
Pierre-Marie Girard,
and
P S. Sow
* To whom correspondence should be addressed. E-mail: roland.landman{at}univ-paris-diderot.fr.
 |
Abstract |
|---|
We report the results of a pilot open-label trial of a tenofovir (TDF)/emtricitabine (FTC)/efavirenz (EFV) combination conducted in Dakar, Senegal. Forty HIV-1-infected patients, naive of antiretroviral treatment and without active opportunistic disease, were included and followed through 96 weeks. At weeks 48 and 96, respectively, 82.5% and 85% of patients had HIV-1 RNA <400 copies/mL (72.5% and 77.5% with HIV-1 RNA <50 copies/mL). Between baseline and week 96, the mean (SD) CD4 count increased from 126 (102) to 338 (155) cells/mm3. The mean (SD) creatinine clearance decreased from 92 (36) to 73 (19) mL/min (P = .001). Treatment adherence was at least 94% at all scheduled visits. The efficacy and tolerability of a TDF/FTC/EFV combination were high and similar to those observed in Northern countries. This drug combination can be recommended in limited-resource countries, as did the World Health Organization (WHO) and should be made readily available as a fixed-dose combination.
First published on September 15, 2009
Journal of the International Association of Physicians in AIDS Care (JIAPAC) 2009, doi:10.1177/1545109709344352
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
|
|
